Detalles de la búsqueda
1.
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Ann Hematol
; 103(6): 2123-2131, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38436671
2.
Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma.
Eur J Haematol
; 110(3): 296-304, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36433728
3.
Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variant.
Genes Chromosomes Cancer
; 60(4): 287-292, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33277788
4.
Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience.
Ann Hematol
; 100(3): 809-816, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33496839
5.
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.
Am J Hematol
; 95(12): 1562-1571, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32936982
6.
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Oncologist
; 23(4): 454-460, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29317554
7.
Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.
Int J Mol Sci
; 19(7)2018 Jul 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30021955
8.
Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer.
Int J Cancer
; 139(3): 657-63, 2016 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26996277
9.
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Oncologist
; 21(9): 1107-12, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27382029
10.
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Ann Hematol
; 95(7): 1107-14, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27103007
11.
The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo.
BMC Cancer
; 15: 738, 2015 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26483043
12.
Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study.
Cancers (Basel)
; 15(3)2023 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36765566
13.
Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL).
Cancers (Basel)
; 14(17)2022 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36077822
14.
Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years.
Anticancer Res
; 42(12): 5825-5832, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36456157
15.
High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group.
Transplant Cell Ther
; 28(6): 337.e1-337.e10, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35296445
16.
Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.
Blood Adv
; 5(6): 1746-1754, 2021 03 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33749761
17.
The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond.
Cancers (Basel)
; 13(18)2021 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34572927
18.
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis.
Cancers (Basel)
; 12(9)2020 Aug 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32825035
19.
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78.
Front Oncol
; 9: 1530, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32039016
20.
Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.
Oncotarget
; 9(2): 2344-2356, 2018 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29416776